Harry Lam, PhD
Harry Lam, PhD, is Executive Vice President of Technical Operations, JW Therapeutics. Previously, he was Head of Therapeutics Technical Operation at 23andMe, Vice President and Head of Manufacturing at Sanofi and Shire Regenerative Medicine. Prior to Sanofi and Shire, He worked in various leadership roles in CMC and manufacturing engineering at Genentech/Roche. Dr. Lam received his BS in Chemical Engineering from the University of Birmingham, and his PhD in Chemical Engineering from Rensselaer Polytechnic Institute.
Alice Yu, MD PhD
Alice Yu, MD, PhD, is Distinguished Chair Professor and Co-Director of Institute of Stem Cell and Translational Cancer Research at Chang Gung University (Taiwan). She is also the Academician and Visiting Research Fellow of Genomic Research Center at Academia Sinica (Taiwan), Professor in Pediatrics (Pediatric Hematology and Oncology) at UCSD. Dr. Yu earned her MD from the National Taiwan University, and her MS from Yale University, and her PhD in Microbiology and Immunology from University of Chicago.
Dung Thai, MD PhD
Dung Thai, MD, PhD, is Chief Medical Officer of REMD Therapeutics. Prior to REMD, he held leadership positions at several companies in the industry from Atara, Arresto, Anza Biotherapeutics, Gilead Science and Amgen. Dr. Thai earned his BA from Cornell University, and his MD/PhD in Pharmacology from University of Pittsburgh. He was a fellow and clinical instructor in the department of clinical pharmacology at University of California, San Francisco. Dr. Thai was a post-doctoral fellow at the UC Berkeley and Carnegie Mellon University.